Literature DB >> 8892393

Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats.

H Yokoi1, H Arima, T Murase, K Kondo, Y Iwasaki, Y Oiso.   

Abstract

The hypotensive peptide, adrenomedullin (AM), was first isolated from the tissue of human pheochromocytoma. Recently, AM-immunoreactivities have been found in the central nervous system, including the supraoptic and the paraventricular nuclei. In this study, the effect of centrally administered AM on arginine vasopressin (AVP) release was investigated in conscious rats. Intracerebroventricular injection of AM (1.0 microgram/rat) partially but significantly attenuated the plasma AVP increase induced by hyperosmolality (intraperitoneal (i.p.) injection of hypertonic saline (600 mosmol/kg)) at 30 min after the injection. It also significantly attenuated the plasma AVP increase induced by hypovolemia (i.p. injection of polyethylene glycol) at 30 min after the injection. These results suggest that central AM might play an inhibitory role in both osmo- and baro-regulation of plasma AVP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892393     DOI: 10.1016/0304-3940(96)12998-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans.

Authors:  M C Petrie; J E McDonald; C Hillier; J J Morton; J J McMurray
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

2.  Cardiovascular effects of the intracerebroventricular injection of adrenomedullin: roles of the peripheral vasopressin and central cholinergic systems.

Authors:  B Cam-Etoz; N Isbil-Buyukcoskun; K Ozluk
Journal:  Braz J Med Biol Res       Date:  2012-03-01       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.